Table 1

Characteristics at baseline of study population

CharacteristicTotal
(n=31)
Non-responder
(n=11)
Responder
(n=20)
P value
Age (years)68.4±7.172.2±4.066.3±7.60.026
Male (%)19 (61)10 (91)9 (45)0.020
Ischaemic aetiology—n (%)13 (42)7 (64)6 (30)0.128
NYHA III—n (%)21 (69)10 (91)11 (55)0.055
HF duration (months)16 (6–66)39 (14–66)13 (6–60)0.215
Sinus rhythm—n (%)23 (82)8 (73)18 (90)0.224
LBBB—n (%)26 (84)8 (80)18 (95)0.267
QRS width (ms)154±17157±21153±150.556
LVEF (%)26.6±8.124.5±8.627.7±7.70.298
ACE/ARB—n (%)31 (100)11 (100)20 (100)1.000
Beta blocker—n (%)28 (90)10 (91)18 (90)1.000
VO2 peak (mL/kg/min)16.4±5.414.8±3.917.3±6.10.215
  • Values are presented as mean±SD, median with IQR, number or percentage.

  • ARB, angiotensin II receptor blocker; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; VO2 peak, peak oxygen uptake capacity.